Clinical Trial Update: Efficacy and Safety of Intraseasonal Specific Immunotherapy With Depiquick® Birch [Phase 3]

View source ↗

Summary

Phase 3 trial results update on intraseasonal specific immunotherapy with Depiquick Birch for allergic rhinoconjunctivitis has been completed, highlighting effi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinoconjunctivitis

Drugs mentioned

• Depiquick Birch (birch pollen extract)

Snippet

Sponsor: Novartis | Conditions: Allergic Rhinoconjunctivitis | Phase 3 | Status: COMPLETED